Results of a Phase 1 Clinical Trial of Belantamab Mafadotin in RRMM | Shebli Atrash, MD | IMS 2024

My name is Shibli Atrash. I'm a physician at the Levine Cancer Institute, Charlotte, North Carolina. During IMS 2024 here in Brazil, we are presenting three different projects. The first one is the results from phase one clinical trial of Belentimab, carfilzomab, linolidomide, and dexamethasone. For patients who have received one to three prior lines of treatment, multiple myeloma, adaptor-fractor in disease, in this presentation we identified the maximum tolerated dose of 1.9 milligrams per kilogram as the other month of Belentimab methadotin with a backbone of standard dosing, KRD, carfilzomab, linolidomide, and dexamethasone. We will present the data about the death of response. Suffice to say we achieved deep responses with this regimen. Also, we go over the adverse events that are associated with the addition of Belentimab methadotin to the backbone of KRD. As we all know, Belentimab methadotin can cause keratitis, and the hope of this trial is to give the drug every other month to decrease the incidence of keratitis. Overall, despite the high signal for keratitis, it seemed to be very well managed with those delays, basically, and those reductions as a backup method for avoiding those severe adverse events. It's also notable in this trial that our infection signal was much lower than other previously reported monoclonal antibodies or CAR-Ts that were going after the BCMA target, allowing us to harvest the benefits of targeting BCMA without dealing with severe infection adverse events. Given those results, we feel that there is a space for Belentimab methadotin to proceed to be administered to newly diagnosed multiple myeloma patients in a quadriplet regimen in combination with KRD for patients with high-risk multiple myeloma. Recently, we have seen that the addition of monoclonal antibody against CD38 service antigen to KRD backbone have increased the responses for multiple myeloma patients. At the same time, in the DREAM7 trial, we saw that Belentimab methadotin outperformed anti-CD38 monoclonal antibodies in relapsed refractory multiple myeloma patients. So we were thinking, especially with the combination of portisumab and dexamethasone, so we're thinking we can use a quadriplet regimen with Belentimab methadotin and KRD for patients with high-risk multiple myeloma who are transplant eligible or transplant ineligible. This trial will be taking off soon. It's a multi-center trial and hopefully we'll have more updates soon.